Lisdexamfetamine Dimesylate
Capsule
Current Active — Day 1035
Lower impact — Multiple manufacturers (4 known suppliers) produce this drug, which may allow alternative sourcing.
FDA shortage record
- Substance
- Lisdexamfetamine Dimesylate
- Manufacturers / suppliers
-
- Hikma Pharmaceuticals USA Inc.
- Hikma Pharmaceuticals USA, Inc.
- Dosage form
- Capsule
- Presentation
- Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)
- Route(s)
- ORAL
- Therapeutic category
- Psychiatry
- Package NDC
0054-0373-25- Initially posted
- 07/14/2023
- Days on shortage list
- 1035
- Current FDA status
- Current
- Shortage entries (current dataset)
- 4 records for Lisdexamfetamine Dimesylate — repeat offender
Reason and context
Reason reported: Shortage of an active ingredient
Available on allocation
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
6740a621-9bec-4178-a4fc-a3fc89f34e0a). - FDA UNII identifier:
SJT761GEGS. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.